CSL's CFO to head flu vaccines business

CSL's CFO Gordon Naylor has been promoted to head the group's newly created global flu vaccine business.

CSL has appointed its chief finance officer Gordon Naylor as the head of its new global flu vaccine business.

CSL plans to launch the business in early 2016 once it has bedded down its $US275 million ($A354.50 million) acquisition of Novartis's global flu vaccine business.

The combination of the Novartis business with CSL's flu vaccine subsidiary, bioCSL, will create the world's second biggest influenza vaccine supplier.

Mr Naylor joined CSL in 1987 and has held several senior management positions, including chief financial officer since 2010.